Browsing by Subject "Bevacizumab"

Article

Cancer of unknown primary site: 20 questions to be answered

Pavlidis, Nicholas; Pentheroudakis, George (2010)

Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

Article

Cancer of unknown primary: What kind of chemotherapy? what kind of disease?

Pentheroudakis, George; Pavlidis, Nicholas (2009)

Article

Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pentheroudakis, George; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas (2010)

Article

Carcinoma of unknown primary (CUP)

Pavlidis, Nicholas; Fizazi, K. (2009)

Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

Article

The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Cutsem, E. van; Dicato, M.; Geva, R.; Arber, N.; Bang, Y.; Benson, A.; Cervantes, A.; Diaz-Rubio, E.; Ducreux, M.; Glynne-Jones, R.; Grothey, Axel; Haller, D.; Haustermans, K.; Kerr, D.; Nordlinger, B.; Marshall, J.; Minsky, B. D.; Kang, Y. K.; Labianca, R.; Lordick, F.; Ohtsu, A.; Pavlidis, Nicholas; Roth, A.; Rougier, P.; Schmoll, H. J.; Sobrero, A.; Tabernero, Josep; Velde, C. van de; Zalcberg, J. (2011)

Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics ...

Article

Forty years experience of treating cancer of unknown primary

Pavlidis, Nicholas (2007)

Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...

Article

Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review

Boussios, Stergios; Seraj, E.; Zarkavelis, George; Petrakis, Dimitrios; Kollas, Aristomenes; Kafantari, Aikaterini; Assi, A.; Tatsi, K.; Pavlidis, Nicholas; Pentheroudakis, George (2016)

Background Cervical cancer is the fourth most common cancer affecting women worldwide. Despite advances in screening and human papillomavirus (HPV) vaccination, a significant number of women present with or develop advanced ...

Article

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review

Pentheroudakis, George; Greco, F. A.; Pavlidis, Nicholas (2009)

Background: Gene expression profiling platforms were recently shown to accurately assign cancer of unknown primary (CUP) to a primary tissue of origin, with unknown impact on patient outcome. We examined chemotherapy ...

Article

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

Mauri, D.; Polyzos, N. P.; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2008)

Background: Many systemic nonhormonal regimens have been evaluated across several hundreds of randomized trials in advanced breast cancer. We aimed to quantify the relative merits of these regimens in prolonging survival. ...

Article

Neuroendocrine carcinoma of unknown primary: A systematic review of the literature and a comparative study with other neuroendocrine tumors

Stoyianni, A.; Pentheroudakis, George; Pavlidis, Nicholas (2011)

Introduction: Neuroendocrine carcinomas of unknown primary (NCUP) represent a specific subset with relatively favorable prognosis. Data on biology, management and outcome of NCUP patients have not been systematically ...

Article

Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets

Pavlidis, Nicholas (2012)

Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the ...

Article

Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection

Constantinidou, Anastasia; Cunningham, David; Shurmahi, F.; Asghar, Uzma; Barbachano, Yolanda; Khan, Aamir; Mudan, Satvinder; Rao, Sudha Ramachandra; Chau, Ian (2013)

Background: Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection. The potential benefit of adding bevacizumab is yet to be defined. The impact of bevacizumab ...

Article

Perspectives for targeted therapies in cancer of unknown primary site

Pentheroudakis, George; Pavlidis, Nicholas (2006)

Cancer of unknown primary site (CUP) ranks as the fourth most common cause of cancer deaths. Regression of the primary, early development of systemic metastases and resistance to therapy are hallmarks of this heterogeneous ...

Article

Probing the unknown in cancer of unknown primary: Which way is the right way?

Pentheroudakis, George; Pavlidis, Nicholas (2010)

Article

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: A translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

Pentheroudakis, George; Kotoula, V.; Fountzilas, E.; Kouvatseas, G.; Basdanis, G.; Xanthakis, I.; Makatsoris, T.; Charalambous, E.; Papamichael, D.; Samantas, E.; Papakostas, P.; Bafaloukos, Dimitrios; Razi, E. D.; Christodoulou, C.; Varthalitis, I.; Pavlidis, Nicholas; Fountzilas, George (2014)

Background: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor ...

Article

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis

Golfinopoulos, Vassilis; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2007)

Background: Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental ...

Article

Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management

Boussios, Stergios; Pentheroudakis, George; Katsanos, K.; Pavlidis, Nicholas (2012)

The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity ...

Article

Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors

Greco, F. A.; Pavlidis, Nicholas (2009)

The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 ...

Article

Treatment of colorectal cancer in the elderly: A review of the literature

Golfinopoulos, Vassilis; Pentheroudakis, George; Pavlidis, Nicholas (2006)

Although major progress has been achieved in the treatment of colorectal cancer, there are still several questions open for discussion concerning the management of elderly colorectal cancer patients. We conducted a review ...